Bone Marrow Dosimetry in Low Volume MHSPC Patients Receiving Lu-177-PSMA Therapy Using SPECT/CT

Overview

Journal EJNMMI Phys

Specialty Radiology

Date 2024 Apr 3

PMID 38568428

Authors

Dagmar Grob

Bastiaan M Prive

Constantijn H J Muselaers

Niven Mehra

James Nagarajah

Mark W Konijnenberg

Steffie M B Peters

Affiliations

Soon will be listed here.

Abstract

Background: Bone marrow toxicity in advanced prostate cancer patients who receive [Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [Lu]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference.

Methods: Eight mHSPC patients underwent two cycles (3 and 6 GBq) of [Lu]Lu-PSMA-617 therapy. After each cycle, five time point (1 h, 1 day, 2 days, 3 days, 7 days) SPECT/CT was performed at kidney level. Bone marrow dosimetry was performed using commercial software by drawing ten 1.5 cm diameter spheres in the lowest ten vertebrae to determine the time-integrated activity. Simplified protocols using only 2 imaging time points and 3 vertebrae were also compared. Blood-based dosimetry was based on the blood sampling method according to the EANM guideline.

Results: Mean bone marrow absorbed dose was significantly different (p < 0.01) for the imaging based method (25.4 ± 8.7 mGy/GBq) and the blood based method (17.2 ± 3.4 mGy/GBq), with an increasing absorbed dose ratio between both methods over time. Bland Altman analysis of both simplification steps showed that differences in absorbed dose were all within the 95% limits of agreement.

Conclusion: This study showed that bone marrow absorbed dose after [Lu]Lu-PSMA-617 can be determined using an imaging-based method of the lower vertebrae, and simplified using 2 time points (1 and 7 days) and 3 vertebrae. An increasing absorbed dose ratio over time between the imaging-based method and blood-based method suggests that there might be specific bone marrow binding of [Lu]Lu-PSMA-617.

Citing Articles

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.

Hu J, Seifert R, Karkampouna S, Gomes C, Xue S, Afshar-Ormieh A Eur J Nucl Med Mol Imaging. 2024; .

PMID: 39704811 DOI: 10.1007/s00259-024-07010-3.

A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?.

Vergnaud L, Dewaraja Y, Giraudet A, Badel J, Sarrut D EJNMMI Phys. 2024; 11(1):65.

PMID: 39023648 PMC: 11554969. DOI: 10.1186/s40658-024-00658-8.

References

. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2003; 32(3-4):5-265. View

Brosch-Lenz J, Delker A, Volter F, Unterrainer L, Kaiser L, Bartenstein P . Toward Single-Time-Point Image-Based Dosimetry of Lu-PSMA-617 Therapy. J Nucl Med. 2023; 64(5):767-774. PMC: 10152120. DOI: 10.2967/jnumed.122.264594. View

Peters S, Prive B, de Bakker M, de Lange F, Jentzen W, Eek A . Intra-therapeutic dosimetry of [Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2021; 49(2):460-469. PMC: 8803803. DOI: 10.1007/s00259-021-05471-4. View

Prive B, Muselaers C, van Oort I, Janssen M, Peters S, van Gemert W . An Update to the Pilot Study of Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. Front Nucl Med. 2024; 2:863101. PMC: 11440840. DOI: 10.3389/fnume.2022.863101. View

Ferrer L, Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener W . Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010; 116(4 Suppl):1093-100. DOI: 10.1002/cncr.24797. View

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B . Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125-135. PMC: 5895095. DOI: 10.1056/NEJMoa1607427. View

Hemmingsson J, Svensson J, Hallqvist A, Smits K, Johanson V, Bernhardt P . Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [Lu]Lu-DOTATATE Treatment. J Nucl Med. 2023; 64(9):1456-1462. PMC: 10478826. DOI: 10.2967/jnumed.123.265484. View

Heck M, Tauber R, Schwaiger S, Retz M, DAlessandria C, Maurer T . Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018; 75(6):920-926. DOI: 10.1016/j.eururo.2018.11.016. View

Bolch W, Eckerman K, Sgouros G, Thomas S . MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009; 50(3):477-84. DOI: 10.2967/jnumed.108.056036. View

10.

Jackson P, Hofman M, Hicks R, Scalzo M, Violet J . Radiation Dosimetry in Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med. 2019; 61(7):1030-1036. PMC: 7383083. DOI: 10.2967/jnumed.119.233411. View

11.

Wiseman G, Kornmehl E, Leigh B, Erwin W, Podoloff D, Spies S . Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003; 44(3):465-74. View

12.

Baum R, Kulkarni H, Schuchardt C, Singh A, Wirtz M, Wiessalla S . 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016; 57(7):1006-13. DOI: 10.2967/jnumed.115.168443. View

13.

Gear J, Cox M, Gustafsson J, Sjogreen Gleisner K, Murray I, Glatting G . EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018; 45(13):2456-2474. PMC: 6208822. DOI: 10.1007/s00259-018-4136-7. View

14.

Prive B, Peters S, Muselaers C, van Oort I, Janssen M, Sedelaar J . Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clin Cancer Res. 2021; 27(13):3595-3601. DOI: 10.1158/1078-0432.CCR-20-4298. View

15.

Svensson J, Ryden T, Hagmarker L, Hemmingsson J, Wangberg B, Bernhardt P . A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016; 3(1):21. PMC: 5031567. DOI: 10.1186/s40658-016-0157-0. View

16.

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A . Dosimetry of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2018; 60(4):517-523. DOI: 10.2967/jnumed.118.219352. View

17.

Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff C . Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7(11):12477-88. PMC: 4914299. DOI: 10.18632/oncotarget.7245. View

18.

Sartor O, de Bono J, Chi K, Fizazi K, Herrmann K, Rahbar K . Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021; 385(12):1091-1103. PMC: 8446332. DOI: 10.1056/NEJMoa2107322. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Peters S, Mink M, Prive B, de Bakker M, de Lange F, Muselaers C . Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. EJNMMI Res. 2023; 13(1):6. PMC: 9873880. DOI: 10.1186/s13550-023-00952-z. View